Vertex Pharmaceuticals VRTX
NASDAQ VRTX
$547.89 -2.98 (-0.54%)
At close: Nov 10, 2026 · 4:00 PM EST

Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)

Updated

Vertex Pharmaceuticals (VRTX) recorded Income from Continuing Operations of $653.6 million in Q3 2026, down 39.6% from $1.08 billion a year earlier and down 40.6% from the prior quarter.

Analysis

Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026) Analysis & Trends

On a TTM basis, Vertex Pharmaceuticals' Income from Continuing Operations came in at $3.98 billion as of Sep 30, 2026, up 8.2% year-over-year; for FY2025, it came in at $3.95 billion.

  • Annual Income from Continuing Operations has a five-year compound annual growth rate of 7.8% (FY2020 to FY2025).
  • Across earlier years, Income from Continuing Operations came in at -$535.6 million in FY2024, $3.62 billion in FY2023 (+9.0%), $3.32 billion in FY2022 (+41.8%) and $2.34 billion in FY2021 (-13.6%).
  • The Q3 2026 figure is the lowest quarterly Income from Continuing Operations since Q1 2025.
  • On a year-over-year basis, Income from Continuing Operations rose in four of the last seven quarters, with growth averaging 1.9%.
  • Peak year-over-year performance for Income from Continuing Operations in the last five years was growth of 59.6% in Q1 2026, against a decline of 41.2% in Q1 2025 at the low end.
  • Per Business Quant, the preceding three quarters came in at $1.1 billion (Q2 2026), $1.03 billion (Q1 2026) and $1.19 billion (Q4 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 210.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 4.22 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 2.51 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 2.43 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 3.25 Bn
10 Vertex Pharmaceuticals 138.78 Bn 110.77 Bn 2.91 Bn 653.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 653.60 Mn
Jun 30, 2026 1.10 Bn
Mar 31, 2026 1.03 Bn
Dec 31, 2025 1.19 Bn
Sep 30, 2025 1.08 Bn
Jun 30, 2025 1.03 Bn
Mar 31, 2025 646.30 Mn
Dec 31, 2024 913.00 Mn
Sep 30, 2024 1.05 Bn
Jun 30, 2024 -3.59 Bn
Mar 31, 2024 1.10 Bn
Dec 31, 2023 968.80 Mn
Sep 30, 2023 1.04 Bn
Jun 30, 2023 915.70 Mn
Mar 31, 2023 699.80 Mn
Dec 31, 2022 818.90 Mn
Sep 30, 2022 930.50 Mn
Jun 30, 2022 810.50 Mn
Mar 31, 2022 762.10 Mn
Dec 31, 2021 770.10 Mn
API Access

Vertex Pharmaceuticals Income from Continuing Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=VRTX&period=max&api_key=YOUR_API_KEY